Opsona Therapeutics Publications

Cancer publications 

Toll-like receptor 2: therapeutic target for gastric carcinogenesis.
McCormack W, Oshima M, Tan P, Jenkins B.
Oncotarget. 2012 Nov;3(11):1260-1.

STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation.
Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P, Jenkins BJ.
Cancer Cell. 2012 Oct 16;22(4):466-78.

Other publications 

Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease
McDonald CL., Hennessy E., Araiz AR., Keogh B., McCormack W., McGuirk P., Reilly M. and Lynch MA.
Brain Behav Immun. 2016 Nov;58:191-200.

The INNs and outs of antibody non-proprietary names.
Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J, Baker MP.
MAbs. 2016;8(1):1-9.

Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.
Reilly M, Miller RM, Thomson MH, Patris V, Ryle P, McLoughlin L, Mutch P, Gilboy P, Miller C, Broekema M, Keogh B, McCormack W, van de Wetering de Rooij J.
Clin Pharmacol Ther. 2013 Nov; 94(5):593-600.

A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.
Marquez Ruiz JF, Kedziora K, Pigott M, Keogh B, Windle H, Gavin J, Kelleher DP, Gilmer JF.
Bioorg Med Chem Lett. 2013 Mar 15;23(6):1693-8.

Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs.
Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, O'Neill LA, McGuirk P, Timmers L, Smeets MB, Akeroyd L, Reilly M, Pasterkamp G, de Kleijn DP.
Circ Cardiovasc Interv.2012 Apr;5(2):279-87.

Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury.
Farrar CA, Keogh B, McCormack W, O'Shaughnessy A, Parker A, Reilly M, Sacks SH.
FASEB J. 2012 Feb;26(2):799-807.

A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.
Ruiz JF, Kedziora K, Keogh B, Maguire J, Reilly M, Windle H, Kelleher DP, Gilmer JF.
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6636-40.

Toll-like receptors as targets for immune disorders.
Keogh B, Parker AE.
Trends Pharmacol Sci. 2011 Jul;32(7):435-42.

Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures.
Ultaigh SN, Saber TP, McCormick J, Connolly M, Dellacasagrande J, Keogh B, McCormack W, Reilly M, O'Neill LA, McGuirk P, Fearon U, Veale DJ.
Arthritis Res Ther. 2011 Feb 23;13(1):R33.

Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule.
Lysakova-Devine T, Keogh B, Harrington B, Nagpal K, Halle A, Golenbock DT, Monie T, Bowie AG.
J Immunol. 2010 Oct 1;185(7):4261-71.

Targeting Toll-like receptors: emerging therapeutics?
Hennessy EJ, Parker AE, O'Neill LA.
Nat Rev Drug Discov. 2010 Apr;9(4):293-307.

Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody.
Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP.
Circulation. 2010 Jan 5;121(1):80-90.

Modulation of toll-like receptor signalling as a new therapeutic principle.
Lepper PM, Triantafilou M, O'Neill LA, Novak N, Wagner H, Parker AE, Triantafilou K.
Mediators Inflamm. 2010;2010:705612.

TLR2 and TLR4 in ischemia reperfusion injury.
Arslan F, Keogh B, McGuirk P, Parker AE.
Mediators Inflamm. 2010;2010:704202.

TRIL, a functional component of the TLR4 signaling complex, highly expressed in brain.
Carpenter S, Carlson T, Dellacasagrande J, Garcia A, Gibbons S, Hertzog P, Lyons A, Lin LL, Lynch M, Monie T, Murphy C, Seidl KJ, Wells C, Dunne A, O'Neill LA.
J Immunol. 2009 Sep 15;183(6):3989-95.

Toll-like receptors and NOD-like receptors in rheumatic diseases.
McCormack WJ, Parker AE, O'Neill LA.
Arthritis Res Ther. 2009;11(5):243.

Ligands, cell-based models, and readouts required for Toll-like receptor action.
Dellacasagrande J.
Methods Mol Biol. 2009;517:15-32.

Diversity and regulation in the NF-kappaB system.
Wietek C, O'Neill LA.
Trends Biochem Sci. 2007 Jul 32(7):311-9.